Teenagers with type 1 diabetes now have the first randomized trial evidence that an SGLT2 inhibitor can protect their kidneys. The ATTEMPT trial, a 22-week double-blind study of dapagliflozin 5 mg added to insulin, found that the drug reduced measured glomerular filtration rate compared with placebo, using iohexol clearance as the kidney-related primary endpoint. The result matters because kidney disease often begins silently in adolescence for people with type 1 diabetes, and no oral therapy has previously shown a direct filtration benefit in this age group.
Why kidney protection in type 1 diabetes needed pediatric proof
SGLT2 inhibitors have reshaped kidney care for adults with type 2 diabetes and chronic kidney disease. But their use in type 1 diabetes has remained contentious, largely because of safety signals. The FDA revised SGLT2 inhibitor labels to warn about ketoacidosis, including cases where blood sugar appeared normal. That warning applied across the drug class, and current prescribing information for dapagliflozin lists type 1 diabetes as an unapproved indication. Clinicians treating adolescents with type 1 diabetes have therefore been left without clear evidence that kidney benefits outweigh the ketoacidosis risk in younger patients.
The ATTEMPT trial directly addresses that gap. By enrolling youth rather than adults, and by measuring kidney filtration with iohexol clearance instead of relying on estimated GFR equations that can be less precise in younger populations, the study provides a physiologic endpoint that is harder to dismiss as a surrogate artifact. The measured GFR reduction in the dapagliflozin group suggests the drug is altering kidney hemodynamics or tissue biology in a way that lowers hyperfiltration, a known early driver of diabetic kidney damage in adolescents. In pediatric practice, hyperfiltration often precedes albuminuria, so a therapy that safely normalizes filtration could, in theory, delay or prevent clinically apparent nephropathy.
ATTEMPT trial design and the transcriptomic dataset that deepens the finding
The ATTEMPT trial report in Nature Medicine describes a double-blind, randomized, placebo-controlled study in adolescents and young adults with type 1 diabetes. Participants received dapagliflozin 5 mg or placebo on top of their existing insulin regimen for 22 weeks, with randomization stratified to balance baseline kidney function and glycemic control. The primary kidney endpoint, measured GFR by iohexol clearance, showed a statistically significant reduction in the dapagliflozin arm versus placebo. Iohexol clearance is considered a gold-standard technique for directly quantifying how much blood the kidneys filter per minute, which makes the finding more reliable than studies that depend on creatinine-based estimates alone.
The magnitude of GFR lowering was modest but directionally consistent with the concept of reducing glomerular pressure. In adults with diabetic kidney disease, such hemodynamic changes are thought to offload stress on the filtration barrier and slow structural injury. Seeing a similar pattern in teenagers raises the possibility that SGLT2 inhibition could intervene earlier in the disease course, before albuminuria or declining eGFR become established. Importantly, the trial design focused on physiologic endpoints rather than hard outcomes like end-stage kidney disease, which would be impractical to study over a short timeframe in adolescents.
Alongside the clinical trial, researchers deposited a gene expression dataset under GEO accession GSE316742 at the NIH-hosted Gene Expression Omnibus. The dataset title describes SGLT2 inhibition reversing metabolic and inflammatory kidney signatures in youth with type 1 diabetes. That language points to a mechanistic story beyond simple hemodynamic changes: the drug may be shifting inflammatory and metabolic gene activity in kidney-related tissues. If confirmed through further analysis, this would suggest that the GFR reduction seen in ATTEMPT is not solely a pressure-lowering effect on kidney blood vessels but also reflects changes in how kidney cells handle metabolic stress and inflammation.
One testable hypothesis is that the observed GFR reduction is driven partly by the anti-inflammatory transcriptomic changes captured in the GSE316742 dataset rather than hemodynamic effects alone. Researchers could investigate this by re-analyzing stored biospecimens from ATTEMPT participants, matching individual biomarker trajectories to GFR changes over the 22-week period. If participants whose inflammatory gene signatures shifted the most also showed the largest GFR reductions, that would strengthen the case for a tissue-level protective mechanism distinct from the blood-pressure effects that SGLT2 inhibitors are already known to produce.
Such integrative analyses would also help clarify whether certain molecular profiles predict who benefits most from dapagliflozin. For example, youth with more pronounced baseline inflammatory signatures might gain larger kidney protection but also face different safety trade-offs. This kind of precision-medicine framing is still speculative, but the existence of a curated transcriptomic dataset linked to a randomized trial provides a rare opportunity to connect molecular biology with clinical physiology in adolescents.
Ketoacidosis risk and the regulatory gap for adolescents
Any enthusiasm about the kidney data has to be weighed against the established safety concern. The FDA’s drug safety communication documented cases of ketoacidosis in patients taking SGLT2 inhibitors, including euglycemic presentations where dangerously high ketone levels developed without the expected spike in blood sugar. Current dapagliflozin prescribing information carries explicit contraindications and warnings about diabetic ketoacidosis risk in type 1 diabetes, as reflected in the agency’s class-wide labeling language.
Adult trials of related drugs in the same class have reinforced the pattern. A randomized controlled trial of sotagliflozin, an SGLT1/2 inhibitor, added to insulin in adults with type 1 diabetes showed efficacy in lowering A1c and body weight but also flagged ketoacidosis as a significant adverse event, leading to cautious regulatory responses. An October 2024 Endocrinologic and Metabolic Drugs Advisory Committee discussion for SGLT2 inhibitors examined how to communicate euglycemic DKA risk, how to structure risk evaluation and mitigation strategies, and whether specific subgroups might tolerate these drugs more safely.
The ATTEMPT trial did not generate long-term safety data beyond its 22-week window. Exact patient-level event counts over years, including rare but serious outcomes like DKA requiring hospitalization, remain unknown for adolescents exposed to dapagliflozin in routine practice. Short-term randomized data can show whether a careful protocol with intensive monitoring keeps DKA rates low, but it cannot fully answer what happens when the drug is used in less controlled environments, such as during intercurrent illness, missed insulin doses, or sports-related dehydration.
This leaves a regulatory and clinical gap. On one side is a physiologic signal suggesting kidney protection during a window of life when hyperfiltration and early injury are common but still reversible. On the other is a known class effect that can produce life-threatening ketoacidosis, sometimes without classic hyperglycemia to trigger early detection. For now, regulators have maintained type 1 diabetes as an unapproved indication for dapagliflozin, effectively signaling that more evidence is needed before routine pediatric use can be endorsed.
How clinicians and families might interpret ATTEMPT
For clinicians, ATTEMPT offers proof-of-concept that SGLT2 inhibition can modify kidney physiology in adolescents with type 1 diabetes. It supports the biological plausibility of early nephroprotection, complements adult data in type 2 diabetes and chronic kidney disease, and opens the door to more targeted pediatric trials. However, it does not yet justify broad off-label prescribing, particularly in settings where ketone monitoring, patient education, and rapid access to acute care are uneven.
Families and teenagers may hear about dapagliflozin as a potential kidney-protective pill and wonder whether they should ask for it. The current evidence suggests that any such discussion must be carefully individualized. Factors like prior DKA history, ability to recognize subtle symptoms, access to blood ketone testing, and comfort with adjusting insulin during illness all matter. Until more safety data accumulate, many endocrinologists are likely to reserve SGLT2 inhibitors for research settings or highly selected patients with close follow-up.
For researchers, the combination of a rigorously measured GFR endpoint and a public transcriptomic dataset is a call to deepen the science. Analyses that integrate kidney physiology, gene expression, and clinical safety outcomes could clarify whether specific dosing strategies, patient characteristics, or adjunctive monitoring tools can tilt the balance toward net benefit in youth. Future trials might also explore lower doses, intermittent use, or combination approaches designed to capture kidney benefits while minimizing DKA risk.
ATTEMPT does not resolve the SGLT2 debate in type 1 diabetes, but it shifts the conversation. Instead of asking whether these drugs can affect kidneys in adolescents, the question now is how to harness that effect safely, or whether the risk profile will ultimately prove too steep. The answers will depend on longer-term follow-up, more granular safety analyses, and continued dialogue among regulators, clinicians, patients, and researchers about what level of risk is acceptable in the pursuit of early kidney protection.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
